| 4.4 -0.28 (-5.98%) | 12-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.46 |
1-year : | 6.33 |
| Resists | First : | 4.67 |
Second : | 5.42 |
| Pivot price | 4.69  |
|||
| Supports | First : | 3.47 |
Second : | 2.88 |
| MAs | MA(5) : | 4.73 |
MA(20) : | 4.53 |
| MA(100) : | 3.28 |
MA(250) : | 0 | |
| MACD | MACD : | 0.2 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 50.2 |
D(3) : | 58.8 |
| RSI | RSI(14): 50 |
|||
| 52-week | High : | 6.15 | Low : | 2.2 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ OBIO ] has closed above bottom band by 32.3%. Bollinger Bands are 90.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.71 - 4.74 | 4.74 - 4.77 |
| Low: | 4.31 - 4.34 | 4.34 - 4.37 |
| Close: | 4.35 - 4.4 | 4.4 - 4.45 |
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Tue, 02 Dec 2025
Orchestra BioMed Grants New Hire Stock Options as Clinical Programs Advance - MyChesCo
Fri, 28 Nov 2025
Analyst Confidence in Orchestra BioMed Holdings (OBIO) High Amid Key Clinical and Strategic Advancements - Yahoo Finance
Wed, 26 Nov 2025
Orchestra BioMed Grants Stock Options to New Hires as Part of 2025 Inducement Plan - Quiver Quantitative
Wed, 26 Nov 2025
Orchestra BioMed (Nasdaq: OBIO) announces 151,250-share inducement stock option grants - Stock Titan
Wed, 26 Nov 2025
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Thu, 13 Nov 2025
Orchestra BioMed Holdings, Inc. Provides Significant Business Updates - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 56 (M) |
| Held by Insiders | 3.27e+007 (%) |
| Held by Institutions | 20.6 (%) |
| Shares Short | 744 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.491e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 359.2 % |
| Return on Equity (ttm) | -52.3 % |
| Qtrly Rev. Growth | 2.82e+006 % |
| Gross Profit (p.s.) | -19.7 |
| Sales Per Share | -256.88 |
| EBITDA (p.s.) | 4.03077e+006 |
| Qtrly Earnings Growth | -1.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -60 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 3.71 |
| Dividend | 0 |
| Forward Dividend | 964440 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|